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Abstract
In classical teaching, the lungs were thought of as a sterile environment with the isolation 
of bacteria on sputum or bronchoalveolar lavage sampling felt to represent pathogenic 
colonisation in disease states. This teaching has been over-turned with the discovery of a 
rich microbiome in the respiratory tract. The respiratory microbiome is a huge target for 
novel research in many fields, most notable in that of airway diseases such as asthma and 
chronic obstructive pulmonary disease (COPD). Next-generation sequencing is a culture-
independent method for microbial sampling which has transformed the accuracy and 
speed at which whole microbial communities can be described in studies. This has led 
to an explosion of knowledge regarding the human respiratory microbiome. COPD is 
a common, chronic disease of the respiratory system involving an irreversible airway 
obstruction which places huge burden on patients and healthcare systems alike. The 
respiratory microbiome is different in those who suffer from COPD than in those without 
the disease, but little is known as to the role of the microbiome in disease pathogenesis 
or manifestation. This chapter aims to outline the advances in sequencing methods in 
relation to the microbiome and establish a description of the respiratory microbiome in 
health and in COPD. We will describe the existing literature on the topic and discuss 
potential key areas for future research.
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1. Introduction
Chronic obstructive pulmonary disease (COPD) is a common, chronic respiratory disorder 
which affects millions of people worldwide [1]. It causes significant morbidity and mortal-
ity and poses a huge burden on healthcare systems through recurrent hospital admissions. 
Indeed, it was the fifth leading cause of death worldwide in 2002 and is estimated by the WHO 
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to become the third leading cause of death internationally by 2030 [2]. In essence, COPD is 
characterised by an obstructive ventilatory deficit that is rarely reversible. Pathogenesis of the 
disease is most strongly associated with smoking though, certainly, there are other factors 
which can contribute to its development. Despite the ever-increasing prevalence of COPD 
worldwide, the exact roles of various causative factors and underlying disease mechanisms 
are not fully understood.
One such potential causative factor is the human microbiome, the collection of all the 
genomes of microorganisms living in association with the human body both in health 
and disease. The microbiota is composed of bacteria, fungi, viruses, protozoa and archaea 
(single-cell organisms). Microbial cells in humans are estimated to outweigh human cells 
by a ratio of 10 to 1, and microbial genes outweigh human genes by a factor of between 
100 and 1000 [3]. Therefore, unsurprisingly, the microbiome has been implicated in many 
diseases across varied body systems including arthritis, colorectal cancer and inflamma-
tory bowel disease [4, 5]. However, more recently attention has been paid to the role of 
the human microbiome in chronic respiratory diseases such as asthma, cystic fibrosis and 
COPD.
This chapter aims to explore the meaning of the microbiome and how it came to be such a cur-
rent and relevant topic for high-level investigative research in the area of respiratory disease. 
We aim to review the existing literature on the topic and particularly explore the relationship 
between the microbiome and COPD exacerbation in terms of both infective and non-infective 
events. We will discuss the perceived importance of the gut microbiome with reference to 
respiratory health and disease and pay particular attention to the so-called gut-lung axis. 
Finally, we will discuss some potential topics for novel research in the field of microbiome 
analysis and discuss future directions for research.
2. The human microbiome: technological advances
Recent advances in next-generation sequencing technologies have caused a quantum leap 
in the analysis of microbial species in various body systems. The cornerstone of these tech-
nologies involves extraction, replication, and identification of specific highly conserved 
genes which are reproducible across a whole host of microbes. Total DNA is extracted 
from the given sample type, e.g., bronchoalveolar lavage, tissue biopsy samples, etc., and 
specific genes are polymerase chain reaction (PCR)-amplified using universal PCR prim-
ers to create amplicons. For bacteria, DNA coding for the 16S rRNA gene can be amplified 
and contains both variable sequence regions V1–V9 and the aforementioned highly con-
served region present in all prokaryotes. 18S rRNA/internal transcribed spacer (ITS) genes 
are amplified and assessed for fungi and protozoa. The 18S rRNA gene is the conserved 
gene across these species, and analysis can be coupled with variable internal transcribed 
spacer (ITS) regions in order to achieve interspecies separation. Amplicons are then ana-
lysed using next-generation sequencing which allows rapid, simultaneous analysis, with 
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sequences thus clustered into operational taxonomic units (OTUs). OTUs are then identi-
fied to the level of species, family or genus, by analysis against a reference database. In 
this way, microbial species can be rapidly and reliably identified in a culture-independent 
manner. Further to this, relative abundance of species in a given sample can be calculated 
to establish the richness and evenness of the microbiome in a system. This advance in 
technology has been responsible for the identification of the components of the gut micro-
biome in health, and much research on the microbiome of other systems has begun from 
this point [6].
There are a few key limitations involved in 16S rRNA and 18S rRNA/ITS gene sequencing 
methods for identification of bacterial and fungal species. Both techniques rely on the avail-
ability of highly specific, non-biased PCR primers as well as rich and varied reference librar-
ies. The quality of PCR primers and references is generally held to be very high in the case of 
bacterial 16S rRNA sequencing [7] but less so in the case of fungal sequencing. Furthermore, 
little information is gained from both these methods about the biological function of these 
microbes. Despite this, they are considered to be cost-effective methods for assessing micro-
bial diversity in a given sample.
Whole-genome shotgun sequencing is an advance on the above techniques whereby long 
DNA strands can be sequenced and identified rapidly. DNA strands are sheared into ran-
dom fragments and cloned into a vector, historically E. coli. Clones are then sequenced to 
produce reads, and reads in turn are assembled into the original sequence using software 
programmes. This technique not only identifies microbes but can also infer information 
regarding biological function encoded in the whole genome. However, due to the massive 
amounts of complex DNA data processed, and the long reads that tend to be generated from 
this method, the system is open to errors. This is also a far more expensive method for DNA 
sequencing.
Next-generation sequencing employs similar methods to shotgun sequencing but generates 
hundreds of thousands of shorter reads in a smaller timeframe. This term is synonymous with 
high-throughput sequencing and encompasses multiple fast, effective, accurate sequencing 
methods. Some potential limitations include the presence of host DNA in the original sample, 
high costs of these methods and some difficulty drawing meaningful conclusions from vast 
quantities of extremely complex data.
Both 16S rRNA sequencing and next-generation sequencing are in use in laboratories world-
wide, and both contribute to the advancement of our understanding of the microbiome 
through quick and accurate analysis of samples. As these technologies continue to advance 
and become more refined, they will become more affordable and sophisticated in coming 
years, allowing accessible DNA sequencing to come to the fore. Further analysis of RNA r and 
proteins can be achieved through the techniques of metatranscriptomics and metaproteomics, 
and this can give us information about genes and pathways in the context of microbiome sam-
pling. See Table 1 for a summary of terms relating to the various DNA sequencing techniques 
we have discussed above.
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3. The respiratory microbiome
For a long time, the respiratory system was thought of as a fully sterile environment. Culture 
isolates from sputum and bronchoalveolar lavage samples were felt to exclusively represent 
pathogenic colonisation in disease states and exacerbation. However, this classic teaching was 
challenged, only in 2009, with the publication of a study undertaken by Hilty et al. [8] which 
employed 16S rRNA sequencing techniques to analyse the microbiota of the lower respiratory 
tract. Subjects carried either a diagnosis of asthma or COPD or were healthy controls, and all 
underwent bronchoscopy to obtain endobronchial brushings from the left upper lobe. The 
microbiome of the nasal cavity and oropharynx was also sampled using surface swabs. This 
study found a similar abundance of microbes in all groups (with a range of 1–10 million cells 
per sample) but with significant differences in microbial composition between the groups 
studied. This was the first study of its kind and was understandably met with scepticism as it 
challenged the formal teaching on the subject [9]. Critics were quick to point out limitations 
of the study design including the fact that lower airway sampling could easily be confounded 
by passage of the bronchoscope through the upper airways, the oropharynx having a signifi-
cantly higher bacterial load than the lower respiratory tract in the order of 1–10 billion cells 
Term Description
Microbiota The collection of all microorganisms living in association with the human body or 
a specific system/environment
Microbiome The genome of the human microbiota
Taxonomy Classification system of organisms
Operational taxonomic unit Categorisation of organisms into species by DNA sequence data
Metagenome The collection of all genes obtained from microorganisms in a habitat
Next-generation sequencing A collective term to describe high-throughput technologies. These allow rapid 
parallel DNA sequencing, i.e. Illumina (Solexa) sequencing, SOLiD sequencing
16S ribosomal gene Gene encoding a 16S subunit of bacterial ribosomes that is highly conserved 
between different bacterial species
16SrRNA gene sequencing Determining the DNA sequence of a 16S ribosomal gene
Metatranscriptomics Analysis of mRNA transcripts associated with an organism
Metaproteomics Analysis of microbial proteins
Metabolomics Analysis of the set of metabolites present within an organism
Richness The number of unique taxonomic units in a sample
Evenness The relative number of taxonomic units in a sample
Alpha diversity A measure of the richness and evenness in a sample
Beta diversity A measure of the similarity of the bacterial composition between samples
Table 1. Summary of terms relating to DNA sequencing techniques.
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per sample. Additionally, it was felt that the relatively new (at the time) process of 16S rRNA 
sequencing would identify dead bacteria in most of the samples and that in order to address 
this potential confounder, a stronger control group was needed. Nevertheless this was an 
interesting and well-designed starting point for the explosion of interest in the area that was 
to follow.
A follow-up study which was similar in design and conducted in ‘healthy smokers’, and 
patients with COPD confirmed the presence of microbial colonies in the lower respiratory 
tract but again was open to the aforementioned potential confounders [10]. These confound-
ers were first addressed by Charlson et al. [9] in 2011 who designed a study using double 
bronchoscopy in six healthy individuals. This involved a process of initial bronchoscopy to 
anaesthetise the airway and then the use of an uncontaminated bronchoscope to collect sam-
ples by brush and lavage. To further reduce the confounding potential of the environment on 
the scope, saline washes were used before the scope was inserted, and this saline was anal-
ysed for bacterial load. Microbiota was found to be present in all lower respiratory samples 
from all patients, but unlike the previously mentioned studies, the order of magnitude was far 
lower, 100–1000 cells per sample. The investigators performed serial lavage, results of which 
showed sequentially diminishing bacterial load. They inferred from this that there is marked 
carry-over from the upper to the lower respiratory tracts. An interesting finding was that low 
levels of DNA were found in the environmental control samples such as the saline washes 
even though these were sterile by culture. Bacterial lines were found to be more abundant 
in the lower airway than the upper, though overall microbiome was more rich in the upper 
airway.
The Hilty trial found that the bronchial tree consists of a rich and varied microbial commu-
nity in all groups tested and confirmed that the individual components of this community 
were different in health and disease [8]. Proteobacteria were found in higher abundance in 
diseased individuals (those with asthma and COPD) than in controls, in particular the well-
known respiratory pathogens Haemophilus, Moraxella and Neisseria. In contrast, Bacteroidetes 
such as Prevotella were found to be far more abundant in healthy controls. Studies since this 
have aimed to further refine our understanding of the now-accepted paradigm of the core 
respiratory microbiome. Various studies have identified varying counts of microbes, and 
it is generally acknowledged that the respiratory microbiome is composed of Bacteroides, 
Proteobacteriae, Firmicutes and Actinobacteriae. The bacterial communities of the lung are 
almost mirrored in the oral cavity, but not in the nose, and some species that show high 
prevalence in the mouth become less abundant lower in the lungs. This has led some to 
believe that oral microbes which migrate to the lower respiratory tract can be selectively 
eliminated from healthy lungs and that those which are not eliminated may contribute to 
low-level inflammatory processes [11].
These studies and numerous similar trials [12, 13] have established the existence of the respi-
ratory microbiome. As technology improves, our ability to sample and analyse these complex 
microbial communities will continue to expand until we have a full understanding of not only 
the composition but also the function of the human respiratory microbiome.
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4. Establishment of the microbiome and the relationship between 
microbiota and the immune system
We have discussed the basis of our understanding thus far of the existence of the microbiome 
in the lung and will go on to explore the role of the microbiome in health and disease. However 
we must first try to decipher the way in which the microbiome is established in humans in 
order to assess whether differences in development may confer lasting effects on the microbi-
ome in later life. It has long been believed that exposure to various bacteria in youth may alter 
the way disease manifests in later life. The so-called hygiene hypothesis states that reduced 
exposure to microorganisms in infancy increases a person’s likelihood to develop allergic-
type diseases by suppressing the natural development of the immune system, particularly the 
innate immune response. It would therefore follow that interruptions in the natural develop-
ment of the microbiome could confer long-lasting differences in the respiratory microbiome 
and that this may have knock-on effects to an individual’s immunity and their propensity to 
develop certain diseases. Much of what is known about the development of the microbiome 
comes from studies of gut microbiota, and we will explore some of this literature in this section 
in order to assess potential links between the microbiome and immune system dysfunction.
Gut microbiota has an established role in the development and maturation of the immune 
response via the so-called education of mucosal surfaces and systemic immune response sys-
tems. Studies suggest that there is a critical development time between months 12 and 24 in 
the relationship between the gut microbiome and the building of the immune system [14]. 
This is demonstrated by the increased risk of the development of inflammatory autoimmune 
disease where dysbiosis is caused by the use of antibiotics at a critical time in infancy. For 
example, increased rates of immunologic disorders such as asthma and paediatric irritable 
bowel disease are associated with antibiotic use in infancy [15].
Traditionally, the human gut has been assumed to be sterile at birth. However, recent 
advances in PCR techniques as outlined above have found evidence of bacteria consistent with 
the maternal gut microbiota in meconium. This is believed to have been transferred via the 
maternal blood stream [16]. Further exposure is from diet and the surrounding environment, 
including the birth canal. Indeed, even the mode of delivery at birth can confer lasting changes 
on the developing microbiome, with those born via caesarean section found to have signifi-
cantly lower abundance and diversity of gut Bacteroides and Actinobacteria species in the first 
3 months of life [17]. At age 12 and 24 months, the infant gut resembles that of the adult [18]. 
The gut microbiome is relatively stable until late in life and has the ability to restore itself [19].
Evidence supports reduced childhood morbidity and mortality not only during the period 
of lactation but also beyond this period and into adulthood [20]. Facultative anaerobes create 
an anaerobic environment where obligate anaerobic bacteria such as Bifidobacterium species 
flourish. Bifidobacteria dominate the gut microbiota, and milk oligosaccharides are known to 
stimulate their proliferation [16]. Along with lactobacilli they appear to maintain resistance 
to pathogenic colonisation, in short acting as so-termed good bugs. Bifidobacteria are rarely 
pathogenic and ferment bacteria to produce short-chain fatty acids (SCFA) [16].
SCFAs are thought to have many functions including important interactions with the 
immune system. Two mechanisms of action for this relationship have been established to 
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date, activation of G-protein-coupled receptors (GPR41 and GPR43) and inhibition of histone 
deacetylase (HDAC) via leukocytes and endothelial cell lines. SCFAs also have a regulatory 
role over leukocyte functions such as production of cytokines (TNF-α, IL-2, IL-6 and IL-10), 
eicosanoids and chemokines. In addition, SCFAs also seem to impact the migratory ability of 
leukocytes to travel to points of inflammation and to destroy microbial pathogens [21].
Intestinal epithelial cells are a key component of the symbiotic relationship between gut 
microbiota and the host. They provide a physical and chemical barrier system to spatially 
separate gut microbiota from the host immune system, preventing unnecessary immune 
responses. Immunological mediators such as cytokines and chemokines are secreted from 
intestinal epithelial cells which are in turn stimulated by gut microbiota-modulated host 
immune responses, maintaining a well-balanced relationship between gut microbes and the 
host immune system [22]. Gut microbiota also have a role in the maintenance of innate immu-
nity. For example, murein lipoprotein from selective gut-symbiotic Gram-negative bacteria 
results in IgG targeting bacterial antigens for removal by phagocytes [23].
In addition, gut microbiota plays an important role in the development of both local and 
remote adaptive immunities as demonstrated by the work with germ-free (GF) mice which 
had significantly lower numbers of CD4+ cells. In other animal model research, the spleens and 
mesenteric lymph nodes of GF animals were shown to have abnormalities such as absent lym-
phocyte zones. Th1/Th2 imbalances have also been demonstrated in GF animal models [24].
New techniques have allowed even specific bacterial species to be associated with the develop-
ment of particular T-cell subtypes. For example, Bacteroides fragilis is involved in the induction 
of the development of a systemic Th1 response via its polysaccharide A (PSA) molecules [21].
There seems to be emerging evidence to suggest a significant relationship between the gut 
microbiome and the respiratory microbiome proposing the existence of a ‘lung-gut axis’. 
When depletion of gut microbiota is achieved in mouse models, the mice are prone to devel-
oping significant pneumonia, and when the gut microbiome is restored, the severity of pneu-
monia decreases [25]. Additionally, this relationship is strengthened by the observation that 
acute changes in the gut microbiota can be achieved by stimulation of the lung with lipopoly-
saccharide [26]. These results indicate the potential for ‘cross-talk’ between the gut and the 
lung and introduce the concept of a ‘whole body microbiome’, dysregulation of which can 
lead to disease in other organ systems.
As we can see, mostly from gut microbiome research trials, there is significant interplay 
between the microbial communities in the gut and the immune system, both adaptive and 
innate immune responses. The microbiome is established in a well-described manner but can 
certainly be greatly influenced by diet, microbial exposures, and even mode of delivery at 
birth. It is reasonable to expect the same interplay to be a feature of the respiratory microbi-
ome, but further work is needed to establish this relationship.
5. The microbiome in stable COPD
We have explored the current knowledge of the respiratory microbiome in health and the 
role it plays in inflammatory processes; however, we will now discuss what is known about 
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the role of the respiratory microbiome in relation to COPD. Haemophilus influenzae, Moraxella 
catarrhalis and Streptococcus pneumoniae are known to be the most abundant colonisers in the 
lungs of COPD patients [27]. Consequently, they are the most frequently isolated pathogens 
in sputum samples and bronchoalveolar lavage in this patient group, both in health and dis-
ease. These microbes remain prominent across multiple studies of the COPD lung and are 
implicated in driving multiple inflammatory pathways in the diseased lung [28, 29]. This 
certainly has many profound clinical effects on patient groups with COPD. For example, a 
recent study found that patients who were chronically colonised with H. influenzae were more 
likely to have increased airway inflammation and decreased lung volumes when compared 
with those not colonised [30].
In healthy lungs, spatial and temporal microbial diversity in the same lung is less than the 
diversity seen between individuals and seems to be mostly a consequence of microbial elimi-
nation and immigration. The reverse is true in diseased lungs meaning there is wide variation 
in microbial communities in a given patient’s lungs [31]. This is particularly true of COPD 
lungs where very significant temporal and biogeographical variations in diversity and abun-
dance have been seen [32]. Microbial communities are felt to be drastically affected by local 
growth conditions in disease lung. The factors which can affect growth conditions are oxy-
gen tension, pH, relative number of immune cells present in a given area and even blood 
perfusion. The microbiome has been linked to the clinical phenotype of COPD by one group 
who concluded that greater emphysema and increased immune cell infiltration were found 
in those COPD patients who showed decline in the diversity and richness of their respira-
tory microbiome [12]. Indeed more recently, correlation was shown between altered bacterial 
communities as seen in COPD with CT-detectable structural changes in lungs of those COPD 
patients [33].
Reactive oxygen species are postulated to drive the inflammatory processes which lead to 
COPD through activated alveolar macrophages. Bacterial activation of certain NOD-like 
receptors can upregulate the production of these reactive oxygen species in alveolar macro-
phages. Bacterial activation such as this is known to occur in the GI tract, and this potentially 
implicates the GI microbiota in the development of COPD [34]. If gut microbiome can poten-
tially be implicated in driving respiratory inflammation, it is reasonable to wonder whether 
the use of certain probiotic bacterial strains could help to reduced lung-driven inflammatory 
processed. One group has shown favourable outcomes with regard to this hypothesis and 
has found that when alveolar macrophages phagocytose the well-known probiotic strains 
Lactobacillus rhamnosus and Bifidobacterium breve, certain inflammatory pathways are sup-
pressed. In particular their use inhibits cigarette smoke-induced nuclear factor-kB activation 
and the inflammation associated with this pathway [35].
6. The impact of the microbiome on infection and exacerbation
As we have discussed, there is an increasing wealth of evidence indicating the vital role that 
the lung microbiome plays in chronic obstructive pulmonary disease (COPD); however, our 
understanding of the exact role the lung microbiome plays in COPD exacerbation remains in 
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its infancy. While our understanding of the microbiome in humans has vastly expanded in 
recent years, there is still a significant dearth of certainty regarding the dynamics of the lung 
microbiome and its role in disease aetiology. Ambiguity arises from the heterogeneous nature 
of COPD coupled with the diversity and structure of the microbiome, the mediation of host 
inflammatory response and additional external variables such as involvement of antibiotic 
and steroid treatments and environmental factors.
Recent literature contributions have highlighted the central and crucial role of bacteria in 
COPD exacerbations with evidence to suggest that during exacerbations there is a shift in 
microbial diversity within the ecosystem. [36]. An increase in the relative abundance of 
Proteobacteria and a decrease in Firmicutes compared to non-exacerbation samples have been 
observed. Interestingly, there is an increase in Moraxella and Haemophilus populations dur-
ing exacerbations with a concurrent decrease in Streptococcus identified. These shifts in taxa 
composition are in keeping with the findings of Wang et al. [37] who found an overall reduc-
tion in alpha diversity, the microbial diversity within a sample, during exacerbations when 
compared with ‘stable’ samples.
Network analysis has revealed potential interactions between bacterial operational taxonomic 
units (OTUs). Microbial network examination has revealed that a few ‘hub’ OTUs predomi-
nate which are highly connected with multiple other nodes of microbiota. Moreover, many of 
the OTUs demonstrate both ‘coexistence’ and ‘co-exclusion’ patterns between bacterial spe-
cies. Most OTUs have numerous negative connections with other members of the microbiota. 
In particular, Haemophilus has a disproportionately large number of negative connections with 
other OTUs [38]. Consequently, any significant increase in abundance of OTUs is associated 
with a decrease in microbial alpha diversity. Conversely many OTUs demonstrate a strong 
mutual cooperative relationship in tightly connected groups. Indeed, a ‘Like Will to Like’ 
relationship of enrichment promotion among organisms of different species in an ecosystem 
has been well described for intestinal microbiota [39], whereby closely related phylotypes 
display significantly increased abundances or co-occurrences when compared with those less 
closely related species.
In the context of the lung microbiome, the keystone species is a topic that warrants further 
exploration. This inchoate paradigm, which expounds the concept describing how minimal 
fluctuations in the abundances of relatively few bacterial species may profoundly alter the 
microbial community dynamic and potentially impact the human disease state [37]. For 
example, Actinobacteria, a species whose abundance decreases during COPD exacerbations, 
comprises a multitude of metabolically diverse organisms which produce secondary metabo-
lites, including those with antimicrobial activity [40]. Moreover, many Clostridia species are 
known activators of anti-inflammatory T-regulatory cells [41].
Following on, it is possible that the overgrowth of certain OTUs may drive dysbiosis of the 
respiratory tract through remodelling of the normal lung microbial ecosystem which could 
elicit a host pro-inflammatory response [37]. Through dysbiosis of the lung microbiota, 
pathogenic members of the genera Haemophilus and Moraxella can indirectly trigger exces-
sive production of chemokine ligand 8/interleukin 8 (CXCL8/IL-8). This is due to pathogenic 
Haemophilus and Moraxella members directly causing inflammation by exposing the host to 
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lipopolysaccharides and other pathogen-associated molecular patterns [41]. This is coupled 
with depletion of species that might in fact contribute to the maintenance of community and 
host immune homeostasis and fight the negative effects of the above pathogenic species.
As a corollary, one potential biomarker for overall microbial lung population is sputum 
CXCL8/IL-8, which is directly associated with microbiome community structure and diver-
sity. It has a prominent role in COPD [42] whereby it induces airway inflammation by recruit-
ing neutrophils and upregulating mucin genes, causing mucus production. As such, sputum 
CXCl8/IL-8 levels correlate well with COPD severity [43].
Given the heterogeneous nature of COPD, identification of various phenotypes has helped in 
identifying the most suitable and specific treatment for exacerbations. The microbiome exac-
erbation phenotypes have been defined as bacterial, viral, eosinophilic, bacterial/viral combi-
nation, bacterial/eosinophilic combination or pauci-inflammatory [36]. There is a significant 
difference in microbiome composition at both the phylum and genus levels between different 
phenotypes but particularly between bacterial and eosinophilic exacerbations. Furthermore, 
there is a significant decrease in the Proteobacteria/Firmicutes ratio in the eosinophilic subgroup, 
compared to the other phenotypes, during exacerbations. This correlates with the hypothesis 
that exacerbations involving bacteria and eosinophils reflect fundamental differences in their 
immunopathogenesis, while virus-related exacerbations are often associated with both bacte-
rial infections and an increase of eosinophils [36]. Consequently, the presence or absence of 
eosinophilic inflammation could therefore potentially be used as a biomarker for stratification 
of the underlying associated microbiome and subsequent treatment strategies.
With regard to COPD exacerbation treatment strategies, it has become apparent that ‘stan-
dard-of-care’ therapy involving antibiotics and steroids has a significant effect on the phylo-
genetic composition of the community. Alterations in the abundance of individual taxa are 
directly linked to the use of steroids and/or antibiotics. Indeed, the use of oral corticoste-
roids has been found to decrease microbial alpha diversity, with an enrichment of some taxa, 
mainly Proteobacteria, and an increase in the Proteobacteria/Firmicutes ratio has been identified. 
In contrast, a reversal of this trend, i.e. an increase in microbial alpha diversity and micro-
bial composition changes, has been observed when treatment of COPD exacerbation involves 
antibiotics (with or without steroids) [37, 43]. Furthermore, this effect of antibiotic and steroid 
treatment on the microbiome structure appears to be prolonged, emphasising the importance 
of patient phenotype stratification.
7. A functional analysis of COPD airway microbiome
A recently developed bioinformatics tool, PICRUSt [41, 44], has enabled researchers to explore 
the predicted functional capacity of the microbiota involved in the changes observed dur-
ing exacerbation and response to treatment. Hitherto, high-resolution metagenomic profiling 
has been almost prohibitively expensive and intensive computationally. PICRUSt can predict 
the presence and relative abundance of gene families within the microbiome. This predic-
tion is based on 16S rRNA data and can be used at any time point or, in this case,  during an 
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 exacerbation. The intention is to identify and characterise variations in microbiome differ-
ential associated with features of exacerbations. Predicted functions that are enriched dur-
ing exacerbation include pathways involved in apoptosis, p53 signalling, along with those 
involved in bacterial and viral infection, e.g. Influenza A virus and Staphylococcus aureus. On 
the other hand, depleted predicted functions include those pathways involved in the response 
to viral infection, e.g. RIG-I-like receptor signalling. Other known pathways depleted during 
COPD exacerbation include those involved in the production of betalain and indole alka-
loid—known for their antimicrobial properties—and those involved in flavonoid and steroid 
biosynthesis, known anti-inflammatory mediators [41]. In keeping with this hypothesis, a 
reversal of the above compositional shifts in the microbiome can be observed during treat-
ment and indeed may play a role in the recovery from exacerbation.
Observations suggest that while variation between test subjects in microbial community 
dynamics at exacerbation is seen, the compositional shifts overall for a particular microbiome 
are not very large. These finding suggests that exacerbations of COPD could result from the 
cumulative effects of many small-scale changes in the community composition. Hence, these 
functional predictions may describe not only an increase in pathogen-elicited inflammation 
but also the loss of crucial protective functions in the microbiome.
8. Conclusions and areas for future research
Throughout this chapter, we have outlined the relatively new field of microbiome analysis 
in respiratory disease. The lungs were once thought to be sterile, and since this presumption 
was first over-turned in 2009, there has been a veritable explosion in the wealth of knowledge 
surrounding the topic. We are now beginning to understand the vital role which the micro-
biome plays in the development and propagation of many major respiratory diseases. This 
increased knowledge has been made possible by significant advances in culture-independent 
sequencing methods which we have outlined. As these intricate systems continue to develop 
and improve, our ability to analyse microbial samples will continue to strengthen with these 
techniques becoming more and more widespread and accessible.
Much is known about the gut microbiome, with respiratory microbiome research also on 
the increase. We have outlined some emerging evidence to suggest interplay between these 
two large micro-systems, and the hypothesis that they can mutually influence each other in 
health and disease is a fascinating concept. Certainly, more work needs to be done in this area 
through observational human research, as most of the literature involves animal models.
We now are in the position to not only name the components of a given microbiome but also 
to analyse their functions through next-generation metagenomics sequencing. It is not enough 
to know that the microbiome of the lung is altered in COPD; we must follow on to assess the 
function of these different bacteria and viruses in causing or preventing disease. If we can 
manage to do this in a meaningful and reproducible way for certain diseases such as asthma 
and COPD, then it is reasonable to assume that we can develop novel therapeutic targets for 
these chronic disease states which may alleviate the treatment burden for our patients.
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